Cell
Volume 174, Issue 3, 26 July 2018, Pages 564-575.e18
Journal home page for Cell

Article
Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19

https://doi.org/10.1016/j.cell.2018.06.014Get rights and content
Under an Elsevier user license
open archive

Highlights

  • rs11672691 risk region is bifunctional with both promoter and enhancer activity

  • This SNP modulates the bifunctionality and reciprocal expression of PCAT19 isoforms

  • PCAT19-long interacts with HNRNPAB to activate a subset of cell-cycle genes

  • PCAT19-long regulates cell proliferation, tumor growth, and metastasis

Summary

The prostate cancer (PCa) risk-associated SNP rs11672691 is positively associated with aggressive disease at diagnosis. We showed that rs11672691 maps to the promoter of a short isoform of long noncoding RNA PCAT19 (PCAT19-short), which is in the third intron of the long isoform (PCAT19-long). The risk variant is associated with decreased and increased levels of PCAT19-short and PCAT19-long, respectively. Mechanistically, the risk SNP region is bifunctional with both promoter and enhancer activity. The risk variants of rs11672691 and its LD SNP rs887391 decrease binding of transcription factors NKX3.1 and YY1 to the promoter of PCAT19-short, resulting in weaker promoter but stronger enhancer activity that subsequently activates PCAT19-long. PCAT19-long interacts with HNRNPAB to activate a subset of cell-cycle genes associated with PCa progression, thereby promoting PCa tumor growth and metastasis. Taken together, these findings reveal a risk SNP-mediated promoter-enhancer switching mechanism underlying both initiation and progression of aggressive PCa.

Keywords

prostate cancer progression
risk SNP
lncRNA
bifunctional regulatory element
promoter-enhancer switching
rs11672691
PCAT19
YY1
NKX3.1
HNRNPAB

Cited by (0)

16

Lead Contact